PLRX · XBRL financial data

Pliant Therapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (PLRX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	41,817	7,572	9,685	1,580	0	0
Research and development	66,193	77,549	96,936	127,797	169,310	109,157
General and administrative	17,269	27,558	39,949	57,928	59,055	47,216
Total operating expenses	83,462	105,107	136,885	185,725	228,365	156,373
Operating income (loss)	(41,645)	(97,535)	(127,200)	(184,145)	(228,365)	(156,373)
Interest income	478	—	—	—	—	—
Interest expense	—	0	791	1,267	3,024	2,559
Other income (expense)	(366)	—	—	—	—	—
Income tax expense (benefit)	0	0	0	0	0	0
Net income (loss)	(41,533)	(97,263)	(123,321)	(161,336)	(210,304)	(149,344)
Earnings per share, basic USD per share	(1.95)	(2.71)	(2.94)	(2.75)	(3.47)	(2.43)
Earnings per share, diluted USD per share	(1.95)	(2.71)	(2.94)	(2.75)	(3.47)	(2.43)
Weighted average shares, basic thousands of shares	21,344	35,846	42,016	58,719	60,539	61,367
Weighted average shares, diluted thousands of shares	21,344	35,846	42,016	58,719	60,539	61,367

Fiscal years (PLRX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	50,882	51,665	33,685	63,234	71,188	45,445
Short-term investments	226,012	148,931	297,502	431,011	284,536	145,499
Accounts receivable	9,279	1,998	1,983	0	—	—
Prepaid and other current assets	4,498	6,764	7,058	11,257	6,540	4,464
Total current assets	290,754	209,441	340,311	505,502	362,264	196,448
Property and equipment, net	4,321	4,606	4,486	3,567	5,525	2,940
Right-of-use asset	0	6,330	5,422	1,211	27,243	23,966
Total assets	295,526	221,215	350,613	512,154	396,949	225,228
Accounts payable	2,023	2,971	1,580	4,531	5,960	480
Accrued liabilities	9,576	11,991	8,658	10,219	12,353	9,634
Total current liabilities	11,599	16,831	23,913	28,524	33,218	16,365
Lease liability, non-current	0	5,325	3,429	0	29,439	27,658
Total liabilities	12,465	22,156	37,271	38,578	92,868	44,023
Accumulated deficit	(117,828)	(215,091)	(338,412)	(499,748)	(710,052)	(859,396)
Total stockholders' equity	283,061	199,059	313,342	473,576	304,081	181,205
Total liabilities and equity	295,526	221,215	350,613	512,154	396,949	225,228
Common shares outstanding (cover page) thousands of shares	35,738	36,114	58,940	60,239	61,236	61,915

Fiscal years (PLRX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(41,533)	(97,263)	(123,321)	(161,336)	(210,304)	(149,344)
Stock-based compensation	3,895	10,437	22,598	44,483	37,626	26,234
Net cash from operating activities	(37,271)	(75,443)	(94,631)	(116,361)	(155,503)	(128,336)
Purchases of property and equipment	1,532	1,953	1,760	921	3,848	374
Net cash from investing activities	(210,866)	73,699	(150,204)	(127,012)	140,340	134,290
Net cash from financing activities	213,212	2,527	226,854	274,405	23,117	(31,697)
Net change in cash	(34,925)	783	(17,981)	31,032	7,954	(25,743)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Pliant Therapeutics	24,883	not reported	(12,797)*	61.9M	12.4 quarters	Q2 FY26 10-QJun 30, 2026
Corbus Pharmaceuticals Holdings	23,370	not reported	(29,626)*	19.3M	4.0 quarters	Q2 FY26 10-QJun 30, 2026
Seres Therapeutics	17,528	593	(10,477)*	10.2M	1.1 quarters	Q3 FY26 10-QSep 30, 2026
Oncolytics Biotech	4,115	not reported	(8,138)*	127.5M	0.5 quarters	Q2 FY26 10-QJun 30, 2026
Gyre Therapeutics	43,287	29,105	(16,728)*	111.5M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Volitionrx	2,800	399	(5,160)*	13.6M	0.5 quarters	Q2 FY26 10-QJun 30, 2026
Macrogenics	113,907	32,832	(40,748)*	63.7M	2.8 quarters	Q2 FY26 10-QJun 30, 2026
Inovio Pharmaceuticals	31,526	0	(18,047)*	103.4M	2.0 quarters	Q2 FY26 10-QJun 30, 2026
Whitehawk Therapeutics	85,234	0	(14,529)*	57.0M	13.1 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 6, 2026, 12:49 PM ET. The filing on SEC.gov is the record.